Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: A randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa
Authors:
- John GlaspyJGJohn Glaspy
- David HenryDHDavid Henry
- Ravi PatelRPRavi Patel
- Simon TchekmedyianSTSimon Tchekmedyian
- Steve ApplebaumSASteve Applebaum
- Donald BerdeauxDBDonald Berdeaux
- Richard LloydRLRichard Lloyd
- Russell BergRBRussell Berg
- Matt AustinMAMatt Austin
- Greg RossiGRGreg Rossi
- 1 May 2005
- journal article
- clinical trial
- Published by Elsevier in European Journal of Cancer
- Vol. 41 (8) , 1140-1149
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double‐blind, placebo‐controlled studyBritish Journal of Haematology, 2003
- Randomized, dose‐finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignanciesBritish Journal of Haematology, 2002
- Double-Blind, Placebo-Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving ChemotherapyJNCI: Journal of the National Cancer Institute, 2002
- Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapyBritish Journal of Cancer, 2002
- Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Erythropoietin, Epoetin Beta, in Hematologic MalignanciesJournal of Clinical Oncology, 2002
- Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double-Blind, Placebo-Controlled TrialJournal of Clinical Oncology, 2001
- Clinical Evaluation of Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients: Improvements in Hemoglobin and Quality of Life Are Similar to Three-Times-Weekly DosingJournal of Clinical Oncology, 2001
- Chemotherapy-Induced Anemia in Adults: Incidence and TreatmentJNCI: Journal of the National Cancer Institute, 1999
- Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.Journal of Clinical Oncology, 1998
- Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.Journal of Clinical Oncology, 1997